
CELC
Healthcare · Biotechnology · $3.15B market cap
$64.37+0.20 (+0.3%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -60.0% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -1.47 | -1.33 | +9.5% |
| Aug 13, 2026 | After the close | -1.08 | -1.44 | -33.3% |
| May 14, 2026 | After the close | -0.89 | -0.86 | +3.4% |
| Mar 19, 2026 | Time not confirmed | -1.05 | -0.73 | +30.5% |
| Nov 12, 2025 | After the close | -0.96 | -0.78 | +18.8% |
| Aug 14, 2025 | After the close | -0.84 | -0.93 | -10.7% |
| May 14, 2025 | After the close | -0.86 | -0.81 | +5.8% |
| Mar 25, 2025 | Before the open | -0.67 | -0.75 | -11.9% |
| Nov 14, 2024 | After the close | -0.70 | -0.65 | +7.1% |
| Aug 14, 2024 | After the close | -0.55 | -0.58 | -5.5% |
| May 15, 2024 | After the close | -0.71 | -0.64 | +9.9% |
| Mar 27, 2024 | After the close | -0.75 | -0.61 | +18.7% |
| Nov 13, 2023 | Before the open | -0.53 |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients…
| -0.78 |
| -47.2% |
| Aug 10, 2023 | After the close | -0.46 | -0.58 | -26.1% |
| May 15, 2023 | After the close | -0.43 | -0.47 | -9.3% |
| Mar 23, 2023 | After the close | -0.44 | -0.69 | -56.8% |
| Nov 10, 2022 | After the close | -0.60 | -0.75 | -25.0% |
| Aug 11, 2022 | After the close | -0.48 | -0.55 | -14.6% |
| May 16, 2022 | After the close | -0.51 | -0.53 | -3.9% |
| Mar 23, 2022 | After the close | -0.35 | -0.37 | -5.7% |
| Nov 8, 2021 | After the close | -0.24 | -0.35 | -45.8% |
| Aug 9, 2021 | After the close | -0.21 | -0.66 | -214.3% |
| May 10, 2021 | After the close | -0.20 | -0.21 | -5.0% |
| Feb 16, 2021 | After the close | -0.22 | -0.21 | +4.5% |
| Nov 9, 2020 | After the close | -0.23 | -0.24 | -4.3% |
| Aug 10, 2020 | After the close | -0.18 | -0.17 | +5.6% |
| May 7, 2020 | After the close | -0.17 | -0.17 | 0.0% |
| Mar 12, 2020 | After the close | -0.18 | -0.14 | +22.2% |
| Nov 7, 2019 | After the close | -0.17 | -0.16 | +5.9% |
| Aug 8, 2019 | After the close | -0.18 | -0.15 | +16.7% |
| May 7, 2019 | After the close | -0.20 | -0.16 | +20.0% |
| Feb 26, 2019 | After the close | -0.18 | -0.15 | +16.7% |
| Nov 13, 2018 | After the close | -0.18 | -0.15 | +16.7% |
| Aug 9, 2018 | After the close | -0.17 | -0.15 | +11.8% |
| May 14, 2018 | After the close | -0.19 | -0.16 | +15.8% |
| Mar 15, 2018 | After the close | -0.15 | -0.14 | +6.7% |